Acadia Pharmaceuticals has added novel pain programme to its portfolio with the acquisition of clinical-stage biotechnology company CerSci Therapeutics.
Acadia Pharmaceuticals' stock fell by more than 18% in premarket trading, triggering concerns about some deaths and adverse events in the company's Parkinson's drug, Nuplazid.